Aeglea BioTherapeutics (AGLE) Short Interest Ratio & Short Volume

Short interest is the volume of Aeglea BioTherapeutics shares that have been sold short but have not yet been covered or closed out. As of November 15th, traders have sold 139,700 shares of AGLE short. 4.30% of Aeglea BioTherapeutics' shares are currently sold short. Learn More on Aeglea BioTherapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. AGLE shares currently have a short interest ratio of 3.0. Learn More on Aeglea BioTherapeutics's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 4.30% of Aeglea BioTherapeutics' floating shares are currently sold short.

Aeglea BioTherapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 139,700 shares, an increase of 8.6% from the previous total of 128,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Aeglea BioTherapeutics currently has issued a total of 4,050,000 shares. Some of Aeglea BioTherapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Aeglea BioTherapeutics currently has a public float of 3,250,000 shares.

4.30% of Aeglea BioTherapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Aeglea BioTherapeutics: Y-mAbs Therapeutics, Inc. (8.91%), DiaMedica Therapeutics Inc. (0.94%), Esperion Therapeutics, Inc. (15.43%), ProQR Therapeutics (1.10%), Journey Medical Co. (2.66%), AC Immune SA (2.36%), Korro Bio, Inc. (18.16%), Lexicon Pharmaceuticals, Inc. (18.01%), Aldeyra Therapeutics, Inc (7.91%), LifeVantage Co. (17.26%),

As of the most recent reporting period, the following stocks had the largest short interest positions: RTX Co. ($7.24 billion), T-Mobile US, Inc. ($4.02 billion), Charter Communications, Inc. ($3.72 billion), Occidental Petroleum Co. ($2.80 billion), Lululemon Athletica Inc. ($2.48 billion), Coinbase Global, Inc. ($2.38 billion), Tractor Supply ($2.35 billion), Rivian Automotive, Inc. ($1.79 billion), Royal Caribbean Cruises Ltd. ($1.73 billion), and Moderna, Inc. ($1.71 billion). View all of the most shorted stocks.

Short selling AGLE is an investing strategy that aims to generate trading profit from Aeglea BioTherapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Aeglea BioTherapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of AGLE, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including AGLE, twice per month. The most recent reporting period available is November, 15 2023.